直接肾素抑制剂(DRI)阿利吉仑在慢性肾脏疾病(CKD)中的应用进展  

Advances in the application of direct renin inhibitors(DRI) aliskiren to chronic kidney disease(CKD)

作　　者：韩蕊(综述)[1] 叶志斌(审校)[1] 

机构地区：[1]复旦大学附属华东医院肾内科,上海200040

出　　处：《复旦学报（医学版）》2012年第4期422-427,共6页Fudan University Journal of Medical Sciences

摘　　要：肾素-血管紧张素系统(renin-angiotensin system,RAS)在慢性肾脏疾病(chronic kidney disease,CKD)的发生、发展过程中起重要作用,目前广泛应用的RAS抑制剂血管紧张素转化酶抑制剂(angiotensin convertingenzyme inhibitor,ACEI)和血管紧张素受体阻断剂(angiotensin receptor blocker,ARB)类药物不足以完全阻断肾脏局部的RAS激活。近年来研发成功的直接肾素抑制剂(direct renin inhibitor,DRI)阿利吉仑为更有效地阻断RAS系统提供了新的选择,许多基础和临床研究均证实了DRI在保护肾功能方面的独特优势,且耐受性好、安全性高,本文就这些研究作一综述。Renin-angiotensin system（RAS） plays an important role in the development of chronic kidney disease（CKD）.Angiotensin converting enzyme inhibitors（ACEIs） and angiotensin receptor blockers（ARBs） which have been commonly used in clinical practice do not result in complete suppression of the RAS.Aliskiren,a direct renin inhibitor（DRI）,offers a new and novel approach to inhibit the RAS in chronic kidney disease.Many basic and clinical studies have proved that aliskiren is superior in protecting the renal function than ARBs or ACEIs.And aliskiren has higher safety and better tolerability.The focus of this review is to discuss recent researches about aliskiren on the prevention and management of chronic kidney disease.

关 键 词：肾素-血管紧张素系统(RAS) 直接肾素抑制剂(DRI) 慢性肾脏疾病(CKD) 阿利吉仑 

分 类 号：R322.61[医药卫生—人体解剖和组织胚胎学]